Recently added

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality

Hansen, Doris; Bachy, Emmanuel; bansal, radhika; Rejeski, Kai; Wang, Yucai; Barba, Pere; IACOBONI, GLORIA (American Society of Hematology, 2024-04-23)

Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness

Levy, Pierre; Alflen, Astrid; Apriamashvili, Georgi; ligtenberg, maarten; Vredevoogd, David; Lin, Chun-Pu (Cell Press, 2024-04-08)

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer

Harvey-Jones, Elizabeth J.; Raghunandan, Maya; Robbez-Masson, Luisa; Magraner-Pardo, Lorena; Alaguthurai, Thanu; Yablonovitch, Arielle; Balmaña, Judith; Serra, Violeta (Elsevier, 2024-04)

Complete response of metastatic cutaneous squamous cell carcinoma and multiple locally advanced basal cell carcinomas with concomitant pembrolizumab and sonidegib therapy

Ferrer Fábrega, Berta; González-Cruz, Carlos; MUÑOZ COUSELO, EVA; Ortiz Velez, Carolina; Garcia-Patos Briones, Vicente; Ferrandiz-Pulido, Carla (Elsevier, 2024-03-01)

Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

Spreafico, Anna; Irmisch, Anja; Bessa, Juliana; Au-Yeung, George; MUÑOZ COUSELO, EVA; Bechter, Oliver (Frontiers Media, 2024-03-21)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality

Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer

Complete response of metastatic cutaneous squamous cell carcinoma and multiple locally advanced basal cell carcinomas with concomitant pembrolizumab and sonidegib therapy

Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality ﻿

Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness ﻿

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer ﻿

Complete response of metastatic cutaneous squamous cell carcinoma and multiple locally advanced basal cell carcinomas with concomitant pembrolizumab and sonidegib therapy ﻿

Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure ﻿

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality

Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer

Complete response of metastatic cutaneous squamous cell carcinoma and multiple locally advanced basal cell carcinomas with concomitant pembrolizumab and sonidegib therapy

Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure